Entera Bio Ltd. P/S ratio

P/S ratio of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/S ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its sales per share. It is used by investors mainly because it’s less volatile than P/E and less subject to accounting manipulation. A low P/S ratio compare to historical average or other companies in the same industry might indicate undervaluation.


Highlights and Quick Summary

Current P/S ratio of Entera Bio Ltd. is 35.32 (as of December 30, 2019)
  • P/S ratio for the quarter ending June 29, 2020 was 131.06 (a -1.91% decrease compared to previous quarter)
  • Year-over-year quarterly P/S ratio increased by Infinity%
  • Annual P/S ratio for 2019 was 35.32 (a Infinity% increase from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/S ratio of Entera Bio Ltd.

Most recent P/S ratioof ENTX including historical data for past 10 years.

Interactive Chart of P/S ratio of Entera Bio Ltd.

Entera Bio Ltd. P/S ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 131.06 133.61
2019 35.32 0.0 0.0 35.32
2018 0.0 0.0

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.